

Supplemental Information

SUPPLEMENTAL TABLE 3 Descriptive Comparison of Children on NIV Admitted for Bronchiolitis Who Were Provided EN Either on HFNC or NIPPV

Variables	Fed on NIPPV (<i>n</i> = 25)	Fed on HFNC (<i>n</i> = 60)	<i>P</i>
Age, median (IQR), mo	3.1 (1.6 to 6.9)	6.2 (2.2 to 12.7)	.21
Admission wt, median (IQR), kg	5.4 (4.2 to 8.2)	6.9 (4.5 to 9.5)	.21
WAZ, median (IQR)	−0.8 (−1.1 to 0)	−0.6 (−1.7 to 0.4)	.54
PELOD-2-PDR, median (IQR), %	0.3 (0.3 to 0.9)	0.3 (0.3 to 0.9)	.93
History of previous intubation, <i>n</i> (%)	2 (8)	13 (22)	.37
Comorbidities, <i>n</i> (%)			
Bacterial pneumonia	2 (8)	8 (13)	.48
Chronic lung disease	3 (12)	13 (22)	.29
Gastroesophageal reflux	2 (8)	9 (15)	.38
Genetic disorders	0 (0)	2 (3)	.35
Prematurity (<35 wk gestation)	4 (16)	22 (37)	.06
Stress ulcer prophylaxis, <i>n</i> (%)	6 (24)	9 (15)	.32
Duration of NIV support, mean ± SD, d	3.7 ± 1.6	2.3 ± 1.7	<.01
Hospital LOS, median (IQR), d	7 (4.6 to 8.2)	4.4 (2.8 to 6.7)	.02
Route of EN, <i>n</i> (%)			
Breastfed	2 (8)	11 (18.3)	—
Bottle-fed	14 (56)	38 (63.3)	.15
Nasoenteral tube fed	9 (36)	11 (18.3%)	—
%ΔRR, median (IQR)	−9 (−20 to 0)	−11 (−22 to 6)	.87
%Δ in HR, median (IQR)	−2 (−10 to 5)	−5 (−13 to 0)	.19

—, not applicable.

SUPPLEMENTAL TABLE 4 Descriptive Comparison of Children on NIV Admitted for Bronchiolitis Who Were Provided EN Either by Mouth or by Nasoenteric Tube

Variables	Fed by Mouth (<i>n</i> = 65)	Fed by Nasoenteric Tube (<i>n</i> = 20)	<i>P</i>
Age, median (IQR), mo	6.3 (2.8 to 13.1)	3.4 (2.1 to 9.6)	.41
Admission wt, median (IQR), kg	7.3 (4.5 to 9.5)	5.6 (4.5 to 8.9)	.39
WAZ, median (IQR)	−0.5 (−1.9 to 0.5)	−0.8 (−1.5 to −0.1)	.24
PELOD-2-PDR, median (IQR), %	0.3 (0.3 to 0.9)	0.3 (0.3 to 1.4)	.48
History of previous intubation, <i>n</i> (%)	10 (15)	5 (25)	.32
Comorbidities, <i>n</i> (%)			
Bacterial pneumonia	6 (9)	5 (25)	.06
Chronic lung disease	12 (18)	4 (20)	.87
Gastroesophageal reflux	6 (9)	5 (25)	.06
Genetic disorders	2 (3)	0 (0)	.42
Prematurity (<35 wk gestation)	20 (31)	6 (30)	.94
Stress ulcer prophylaxis, <i>n</i> (%)	12 (18)	4 (20)	.87
Duration of NIV support, mean ± SD, d	1.9 ± 1.4	3.9 ± 1.8	<.01
Hospital LOS, median (IQR), d	3.8 (2.6 to 5.9)	7.1 (5.9 to 9)	<.01
Modality of NIV, <i>n</i> (%)			.08
NIPPV	16 (25)	9 (45)	
HFNC	49 (75)	11 (55)	
%ΔRR, median (IQR)	−11 (−23 to 0)	−6 (−20 to 8)	.44
%Δ in HR, median (IQR)	−5 (−13 to 1)	−4 (−9 to 0)	.54